All News Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.92 ^USD	-4.95%		-0.52%	-80.43%

May. 15	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
May. 15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	May. 15	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	May. 15	MT
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases	May. 15	PR
Ambry Genetics and PacBio Announces Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases	May. 15	CI
Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	May. 13	MT
Pacific Biosciences of California : PacBio Q1 2024 Earnings Presentation	May. 09	PU
Pacific Biosciences: Q1 Earnings Snapshot	May. 09	AQ
Transcript : Pacific Biosciences of California, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q1 Revenue $38.8M	May. 09	MT
Pacific Biosciences of California, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
PacBio Announces First Quarter 2024 Financial Results	May. 09	PR
NewBiologix Launches Next-Generation Sequencing and Optical Mapping Platform to Drive the Next Wave of Biopharmaceutical Discoveries	May. 01	AQ
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	Apr. 22	MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	Apr. 18	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	Apr. 18	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Sector Update: Health Care	Apr. 16	MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink	Apr. 16	MT
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance	Apr. 16	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

All News

Filters